Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice

2001 ◽  
Vol 97 (6) ◽  
pp. 746-750 ◽  
Author(s):  
Adam Giermasz ◽  
Marcin Makowski ◽  
Ewa Kozłowska ◽  
Dominika Nowis ◽  
Małgorzata Maj ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects ◽  
Lewis Lung Carcinoma Model

scholarly journals Effect of Micelle-Incorporated Cisplatin With Sizes Ranging From 8 to 40 nm for the Therapy of Lewis Lung Carcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhicheng Wang ◽  
Yumin Li ◽  
Tong Zhang ◽  
Hongxia Li ◽  
Zhao Yang ◽  
...  
Keyword(s):  
Block Copolymers ◽  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Drug Loading ◽  
Complexation Reaction ◽  
Lewis Lung ◽  
Antitumor Effects ◽  
Lung Carcinoma Cells

Insufficient transport of therapeutic cargo into tumor bed is a bottleneck in cancer nanomedicine. Block copolymers are promising carriers with smaller particle size by ratio modification. Here, we constructed cisplatin nanoparticles with sizes ranging from 8 to 40 nm to study the permeability and therapy of Lewis lung carcinoma. We synthesized methoxypoly(ethylene glycol)2000-block poly(L-glutamic acid sodium salt)1979 loading cisplatin through complexation reaction. The cisplatin nanomedicine has high drug loading and encapsulation efficiency. In vitro data demonstrated that cisplatin nanoparticles had equivalent growth-inhibiting effects on Lewis lung carcinoma cells compared to free cisplatin. In vivo evidences showed cisplatin nanoparticles had superior antitumor effects on the Lewis lung carcinoma mouse model with no obvious side effects. All results indicated that optimizing the ratio of block copolymers to obtain smaller sized nanomedicine could act as a promising strategy for overcoming the inadequate accumulation in poorly vascularized tumors.

scholarly journals Nanoliposomal L-Asparaginase and Its Antitumor Activities in Lewis Lung Carcinoma Tumor-Induced BALB/c Mice

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Thi Thao Do ◽  
Thi Phuong Do ◽  
Thi Nga Nguyen ◽  
Thi Cuc Nguyen ◽  
Thi Thu Phuong Vu ◽  
...  
Keyword(s):  
Side Effects ◽  
Antitumor Activity ◽  
Cytotoxic Activity ◽  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Activities ◽  
Antitumor Effects ◽  
Carcinoma Tumor

Although L-Asparaginase (L-ASP) is an effective chemotherapeutic agent, it has side effects such as fever, skin rashes, chills, anaphylaxis, and severe allergic reactions. Moreover, the short half-life of L-ASP reduces its antitumor activity. To reduce its side effects and broaden its pharmaceutical applications, L-ASP obtained from Pectobacterium carotovorum was subjected to liposomal conjugation. The enzyme was then loaded into liposomes using the hydrated thin-film method. The in vitro cytotoxic activity of liposomal L-ASP was evaluated with the MTT assay using cancerous cell lines, and its antitumor effects were examined in Lewis lung carcinoma (LLC) tumorized mice. The average size of the liposomes containing purified L-asparagine was 93.03 ± 0.49 nm. They had a zeta potential of –15.45 ± 6.72 mV, polydispersity index of 0.22 ± 0.02, and encapsulation efficiency of 53.99 ± 5.44%. The in vitro cytotoxic activity of liposomal L-ASP was less effective against LLC, MCF-7 (human breast carcinoma), HepG2 (human hepatocellular carcinoma), SK-LU-1 (human lung carcinoma), and NTERA-2 (pluripotent human embryonic carcinoma) cells than that of free L-ASP. However, the antitumor activity of liposomal L-ASP was significantly greater than that of untrapped L-ASP at the same doses (6 UI/mouse) in terms of tumor size (6309.11 ± 414.06 mm3) and life span (35.00 ± 1.12 days). This is the first time the antitumor activities of PEGylated nanoliposomal L-ASP have been assessed in LLC carcinoma tumor-induced BALB/c mice and showed significantly improved pharmacological properties compared to those of free L-ASP (P<0.05). Thus, nanoliposomal L-ASP should be considered for its widening applications against carcinoma tumors.

scholarly journals Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma

2014 ◽  
Vol 9 (2) ◽  
pp. 822-828 ◽  
Author(s):  
JUAN FAN ◽  
JIANGRONG DU ◽  
JINGBO WU ◽  
SHAOZHI FU ◽  
DEFENG HU ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects

scholarly journals Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma

2019 ◽  
Vol Volume 11 ◽  
pp. 3469-3479 ◽  
Author(s):  
Yuan Li ◽  
Pan Huang ◽  
Hongju Peng ◽  
Hongcheng Yue ◽  
Min Wu ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects

Synergistic antitumor effects of 131I-LC-1 IgM and IL-12 vaccine on Lewis lung carcinoma

2010 ◽  
Vol 10 (3) ◽  
pp. 284-289 ◽  
Author(s):  
Xiao Ling Yin ◽  
Xuexian Yan ◽  
Ming Wen ◽  
Zhi Ping Peng ◽  
Shao Lin Li
Keyword(s):  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Antitumor Effects

scholarly journals Novel pyrazolopyrimidine derivatives inhibit angiogenesis and tumor growth in a mouse Lewis lung carcinoma model

2015 ◽  
Vol 26 ◽  
pp. ii36 ◽  
Author(s):  
M. Michailidou ◽  
V. Giannouli ◽  
I. Kostakis ◽  
V. Kotsikoris ◽  
P. Marakos ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Lung Carcinoma ◽  
Lewis Lung Carcinoma ◽  
Lewis Lung ◽  
Lewis Lung Carcinoma Model
Sign in / Sign up

Export Citation Format

Share Document